drugset / Trial / NCT06010862
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
Phase 1
Recruiting
36 enrolled
Chongqing Precision Biotech Co., Ltd
The First Affiliated Hospital of Nanchang University · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CEA-positive advanced/metastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.
Timeline
- Start
- 2023-09-30
- Primary completion
- 2025-12-31
- Completion
- 2026-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CEA CAR-T cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | CEA CAR-T cells | Cell therapy | 1e+07 cells/kg | Intravenous |